PYC Therapeutics Limited (OTC:PYCXF) Financings

PYC Therapeutics Limited

Financings

RaiseDateIn US dollars
Rights offering of new fully paid ordinary shares (retail entitlement offer)
Closed: A$47M in the latest tranche · A$1.5 a share · E&P Capital Pty Ltd +2
Dealers: E&P Capital Pty Ltd (co-lead), Barrenjoey Markets Pty Limited (co-lead), Bloom Burton Securities Inc. (co-lead)
Use of proceeds: Advance PYC-003, PYC-002, VP-001 and PYC-001 drug candidates toward registrational or first-in-human trials, plus working capital, R&D and costs
Mar 4, 2026
Private placement of fully paid ordinary shares
Closed: A$128M raised · A$1.5 a share · Bloom Burton Securities Inc.
Dealers: Bloom Burton Securities Inc. (lead)
Buyers: RA Capital Management; Perceptive Advisors; Driehaus Capital Management; MPM BioImpact; Rock Springs Capital; RTW Investments
Use of proceeds: Extend cash runway through CY2030 to deliver human safety and efficacy data for all four drug development programs
Feb 4, 2026US$89.6M
Rights offering of new fully paid ordinary shares
Announced: about A$145.8M · A$1.25 a share · E&P Capital Pty Ltd +6
Dealers: E&P Capital Pty Ltd (co-lead), Barrenjoey Markets Pty Limited (co-lead), Custom Binders Pty Ltd, John Baird, Sami Zouad, Adrian Bonaddio, Dr Yang Sheng Yeo & Ms Esther Mei Yen Liaw as trustees for the Papy Family Trust
Buyers: Alan Tribe (intends to subscribe for New Shares with a value of A$35 million)
Insiders: Chairman Alan Tribe, holding 34% of shares, intends to subscribe for New Shares with a value of A$35 million
Use of proceeds: Advance blinding eye disease, polycystic kidney disease and Phelan-McDermid Syndrome drug candidates through human trials; working capital and offer costs
Feb 17, 2025US$92.69M

Read by 6ix AI from the company's releases